Resources

Our next-generation diagnostic assays have generated novel insights across a broad range of clinical applications.

Access our presentations, publications, and more to see how we’re unlocking the full potential of precision genomics.

Prognostic utility of Minimal Residual Disease (MRD)after curative intent induction therapy for DLBCL:A prospective real-world ctDNA study
December 12, 2023 | Presentation
Optimizing ctDNA limits of detection for DLBCL during first line therapy
December 12, 2023 | Presentation
End of Treatment Response Assessment After Frontline Therapy for Aggressive B-cell Lymphoma: Landmark Comparison of a Singular PET/CT scan vs Ultrasensitive Circulating Tumor DNA
December 12, 2023 | Presentation
MRD-Negativity after Frontline DLBCL Therapy:A Pooled Analysis of 6 Clinical Trials
June 17, 2023 | Presentation
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma
May 30, 2023 | Manuscript
Ultrasensitive ctDNA MRD Monitoring in early stage lung cancer with PhasED-Seq
April 20, 2023 | Poster